Key Highlights
- Prana Thoracic raises additional $3M in oversubscribed Series A extension.
- New investors include cultivate(MD), GenHenn Capital, and Houston Angel Network.
- Funds to accelerate product development and advance clinical and regulatory plans.
- Innovative precision surgical solutions aim to transform lung cancer treatment.
Source: Business Wire
Notable Quotes
- “We are grateful for the overwhelming support from our investors in this financing round. Their confidence in our mission and plan is motivating.” — Joanna Nathan, Chief Executive Officer and Co-Founder at Prana Thoracic
- “We are excited to support Prana Thoracic in their mission to improve lung cancer treatment. Their innovative approach has the potential to significantly impact patient outcomes.” — Dr. R. Sean Churchill, Managing Director at cultivate(MD)
- “The team has made remarkable progress in developing this novel and minimally invasive technique for lung tissue excision, which has the potential to transform the diagnosis and treatment of early-stage lung cancer.” — Edward M. Boyle, MD, Founder and Director at Prana Thoracic
SoHC's Take
Prana Thoracic’s successful Series A extension round underscores the strong investor confidence in the company’s innovative approach to lung cancer intervention. The oversubscribed funding round, supported by notable investors, highlights the potential impact of Prana Thoracic’s precision surgical solutions. This significant financial boost will enable the company to accelerate its product development and advance through critical clinical and regulatory milestones, potentially transforming lung cancer treatment and expanding the application of their technology to other soft tissues. Prana Thoracic’s vision and technological advancements mark a promising step forward in the field of medical technology.
